AMCP Corporate Member Spotlight: Servier
AMCP News & Views recently caught up with Cher Mitchell, PharmD, MBA, MPH, senior director of national accounts for Servier Pharmaceuticals LLC to learn about his company and gain insights on becoming an AMCP Corporate Member.
As you considered becoming a Corporate Member, what tipped the scales?
As a growing leader in oncology, Servier is committed to finding solutions that will address today's challenges. Our oncology portfolio of innovative medicines is designed to bring more life-saving treatments to a greater number of patients, across the entire spectrum of disease and in a variety of tumor types. Currently, we have approved medicines for acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and cholangiocarcinoma (CCA). We have also accelerated our investment in hard-to-treat cancers, with more than 50% of our research and development being dedicated to oncology. Our goal is to serve our patients with the utmost care and treatments to improve their potential for survival. Our decision to become a Corporate Member of AMCP has been driven by a common purpose to improve patients’ lives.
What is your strategy and anticipated innovations for 2022?
We were happy to announce on May 25, 2022, that the U.S. Food and Drug Administration (FDA) approved one of our treatments in combination with azacitidine for the treatment of patients with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy. This therapy is the first targeting cancer metabolism approved in combination with azacitidine for patients with newly diagnosed IDH1-mutated AML.
That approval builds on the established body of evidence, which is now approved across multiple IDH1-mutated cancer types. It also adds to our broad portfolio of medicines prescribed in almost 150 countries.
Beyond our approved products, we have developmental candidates in indications such as myelodysplastic syndromes and glioma, which are just some examples of our investment in innovation. Everything we do is designed to improve the lives of the patients we serve. We are committed to supporting patients throughout their survivorship journey — from diagnosis to remission and beyond.
Our commitment is embodied by our Patient Office, which focuses on how to address the challenges patients face throughout their treatment journey. The information and feedback that we receive from our patient network help us tailor our initiatives toward new partnerships that benefit and meet the needs of the patients.
What’s your one-minute elevator speech about your company?
At Servier Pharmaceuticals, we are dedicated to bringing the promise of tomorrow to the patients we serve. We are a commercial-stage, privately held United States pharmaceutical company. Launched by Servier Group, a unique global organization operating in more than 150 countries and governed by a non-profit foundation, Servier Pharmaceuticals has the resources and network of an established global pharmaceutical company, while operating with the nimble and entrepreneurial spirit of biotech.
We believe all patients should have fair access to the life-saving medications and care that they need. We support collaboration across industries, businesses, and the government to help increase patient access to medications and improve patient care throughout the treatment and survivorship journey. To that end, we make our medications available to eligible healthcare organizations and covered entities at significantly reduced prices under the United States government's 340B Drug Discount Program, meant to serve Medicaid and other in-need populations.
Learn more about AMCP Corporate Membership.